Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. 1995, Boslego, Vaccine

A clinical trial of a vaccine against serogroup B in Chile (40,000 people). As a placebo, a vaccine for other serogroups of meningococcus was used. The effectiveness of the vaccine for 2.5 years was 51%, and among children under 5 years, the efficacy was negative -23%.

Лицензия Creative Commons Content above is licenced under Creative Common Attribution—NonCommercial—NoDerivatives (CC BY-NC-ND) licence,
i.e. it is free for non-commercial distribution and citation with this reference being provided:, amantonio, using the content to create another product or meaning is prohibited., 2017-2019